← Back to Search

Insulin

1 for Coronary Artery Disease (USCDP Trial)

N/A
Waitlist Available
Led By Anthony Furnary, MD
Research Sponsored by Providence Heart & Vascular Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

USCDP Trial Summary

Standard care for patients with diabetes having CABG surgery at Providence St. Vincent Medical Center includes strict control of blood sugar (glucose) levels for 3 days after surgery. This is done through frequent monitoring of blood sugar levels and by giving insulin continuously through a needle into a vein (intravenously). This intensive glucose control has resulted in fewer complications such as serious infections and death, and has shortened the length of the hospital stay for patients. This study treatment is different from standard treatment in that it extends the intensive glucose control beyond the third postoperative day to one full year. Once discharged from the hospital following the CABG procedure, the intense glucose control is done using subcutaneous insulin (a shot under the skin), oral medications, and by measuring blood sugar levels frequently. The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year. Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.

Eligible Conditions
  • Diabetes
  • Coronary Artery Disease

USCDP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year.
Secondary outcome measures
Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.

USCDP Trial Design

2Treatment groups
Active Control
Group I: 1Active Control1 Intervention
strict glucose control (study arm)
Group II: 2Active Control1 Intervention
standard insulin treatment (control arm)

Find a Location

Who is running the clinical trial?

Providence Heart & Vascular InstituteLead Sponsor
SanofiIndustry Sponsor
2,164 Previous Clinical Trials
3,514,860 Total Patients Enrolled
14 Trials studying Coronary Artery Disease
41,613 Patients Enrolled for Coronary Artery Disease
LifeScanIndustry Sponsor
33 Previous Clinical Trials
19,539 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby Apr 2025